Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

Decreased macrophage recruitment correlates with decreased angiogenesis. by Johanna R. Reed (306158)

“…<p>A) Quantification of BrdU incorporation demonstrates that decreased macrophage infiltration does not significantly correlate with a change in epithelial cell proliferation (N.S. = not significant). …”

Host population bottlenecks decrease microbiome diversity. by Michael Ørsted (5926028)

Porcupine plots of the PCA analysis depicting the movement and altitude of the C-alpha atoms throughout the 50 ns simulation in the native and mutant complexes. by Sneha P. (3926957)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Clustering of metastable states using the first 50 ns of post-translational folding trajectories of CAT-III with ligand bound. by Yang Jiang (46459)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”

Pretreatment of Huh-7.5.1 cells with PF-429242 results in a dose-dependent decrease in intracellular DENV-2 NS1 protein abundance and a 3-log decrease in extracellular viral titer. by Anastasia Hyrina (3860455)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Surface tension versus time of the MHS solution (50 mM) and LNC dispersion containing 50 mM MHS as determined by drop tensiometry. by Celia R. A. Mouzouvi (4347937)

Definitions of the features selected [50]. by Yu Zhang (12946)

Topography of the relationship between the change in alpha power decrease and the change in M50 gating ratio. by Tzvetan Popov (315385)

“…B: Relationship between change in alpha power decrease (abscissa, negative values indicate improvement) and pre-to-post-training change in M50 gating ratio (ordinate, positive values indicate changes towards normal, that is, smaller gating ratio) by patient training group based on the ROI in 4A.…”

Cell adhesion to fibronectin is decreased with 50 µM 4N1K treatment. by Pascal Leclair (566971)